FDA OKs AstraZeneca’s Emergent-produced vaccine for export

After facing months of setbacks concerning its contract production of COVID-19 vaccine, Emergent BioSolutions (NYSE:EBS) is making progress.

Most recently, the FDA announced that “certain lots” of AstraZeneca (LON:AZN) COVID-19 vaccine drug substance produced in a facility in Baltimore are acceptable for export.

Last week, the FDA gave the company permission to restart Johnson & Johnson’s (J&J) COVID-19 vaccine production.

While Emergent BioSolutions signed an agreement with AstraZeneca to produce that company’s vaccine in July 2020, the Biden administration required Johnson & Johnson to manage the plant after identifying potential contamination. As a result, FDA ultimately required Johnson & Johnson to discard 60 million doses produced at the Emergent plant.

While the Johnson & Johnson vaccine has won emergency use authorization in the U.S., the AstraZeneca vaccine hasn’t.

The AstraZeneca vaccine, however, has found bro…

Read more
  • 0